T. Scott Reid
Vice President & Global Head of Companion Diagnostics Discovery Life Sciences Inc
Seminars
Thursday 8th October 2026
Beating the Clock: Why Early-Phase CTA Strategy Now Decides the Companion Diagnostics Race
11:00 am
- Oncology drug approval timelines are accelerating making contemporaneous development of a companion diagnostic through traditional pathways more challenging
- Our focus will be accelerating early phase development and deployment of novel clinical trial assays, with early access to solutions that enable fast decision making and clinical trial startup
- Integrating digital pathology and AI solutions into IHC assay development to get more bang for your biomarker buck
